Mirum Pharmaceuticals (MIRM) saw its stock climb approximately 9% on Monday after the company reported that its experimental therapy, volixibat, successfully met the primary endpoint in a Phase 2b clinical trial for primary sclerosing cholangitis (PSC). This rare liver disease currently has no FDA-approved treatments, making the results particularly significant for patients and investors alike.
The VISTAS study enrolled 158 patients with PSC, a condition characterized by scarring of the bile ducts that can lead to liver failure. The trial focused on cholestatic pruritus, the severe itching caused by impaired bile flow, which is one of the most debilitating symptoms of PSC. Patients receiving volixibat 20 mg twice daily experienced a 2.72-point reduction in itch scores on the Adult ItchRO scale, compared to a 1.08-point reduction for those on placebo, yielding a placebo-adjusted difference of 1.64 points. In the main cohort, 55.6% of volixibat-treated patients achieved at least a two-point reduction, versus 26.3% for placebo.
Regulatory Path and Market Implications
Mirum is now moving swiftly toward regulatory milestones. The company has scheduled a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration for this summer, with plans to submit a formal NDA in the second half of 2026. If approved, volixibat would become the first FDA-approved therapy for PSC-associated pruritus.
Analysts have reacted positively to the data. Mani Foroohar at Leerink Partners described the results as opening the door to a potential $1 billion-plus commercial opportunity, while Lisa Walter at RBC Capital Markets noted that the data reduces some risk across Mirum's broader bile-acid pipeline. Mirum shares hit an intraday high of $110.48 before settling at $105.52.
Safety Data Raises Questions
Despite the efficacy signal, the safety profile of volixibat warrants attention. Treatment-emergent adverse events occurred in 93.5% of patients on volixibat, compared to 84.0% on placebo. Diarrhea was notably more common in the volixibat group (40.3% vs. 8.6%), and serious adverse events were reported in 10.4% of treated patients versus 6.2% on placebo. Mirum also observed more frequent liver lab elevations with the drug, which regulators will likely scrutinize during the review process.
Competitive Landscape and Pipeline
While no direct competitors exist for PSC, the broader cholestatic pruritus space has seen recent activity. In March, the FDA approved GSK's Lynavoy (linerixibat) for pruritus in primary biliary cholangitis (PBC), another rare bile-duct disorder. GSK is transferring global rights to Italy's Alfasigma. Ipsen markets Bylvay, an IBAT inhibitor similar to volixibat, for pediatric cholestatic pruritus conditions such as Alagille syndrome.
Mirum is also testing volixibat in PBC through the VANTAGE Phase 2b trial, but topline results have been delayed and are now expected in the first quarter of 2027. The company will report first-quarter 2026 earnings on May 6, with a full-year 2026 revenue forecast of $630 million to $650 million, driven by its existing rare-disease portfolio including Livmarli, Cholbam, and Ctexli.
Full results from the VISTAS study are scheduled for presentation on May 30 at the European Association for the Study of the Liver International Liver Congress, which will provide further detail on volixibat's efficacy and safety.
